Meeting
2015 ASCO Annual Meeting
Anti-tumor efficacy and PD-L1 expression in the tumor microenvironment after poxvirus-based active immunotherapy and PD-1 blockade.
Authors
Stefanie J Mandl
Bavarian Nordic Inc., Mountain View, CA
Stefanie J Mandl , Susan P Foy , Barbara Sennino , Tracy dela Cruz , Evan Gordon , Felicia Kemp , Veronica Xavier , Ryan B Rountree , Alex Franzusoff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Vaccines
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3079)
DOI
10.1200/jco.2015.33.15_suppl.3079
Abstract #
3079
Poster Bd #
405
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.
First Author: Masayuki Shirasawa
First Author: Priya Jayachandran
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Association of an RNA signature (RS) with emergence of ICOS hi CD4 T cells and efficacy outcomes for the ICOS agonist vopratelimab (vopra) and nivolumab (nivo) in patients (pts) on the ICONIC trial.
First Author: Timothy A Yap
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.
First Author: C. Marcela Diaz-Montero